A human umbilical cord highly active mesenchymal stem cell and its preparation method and application
The isolation of highly active MSCs from umbilical cord tissues through a simplified culture system without animal origin has solved the problems of cumbersome isolation methods and low cell activity in the prior art, and achieved efficient and stable cell isolation and clinical applications.
Patent Information
- Application Number
- CN202411195904.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The prior art mesenchymal stem cell (MSC) isolation methods are complicated, the cell activity is low, the yield rate is low, and it is difficult to achieve clinical application. Most culture systems contain animal-derived serum and are not suitable for clinical transformation.
Using a simplified culture system without animal origin, highly active MSCs were selectively isolated from umbilical cord tissue, and primary and subcultures were carried out through a combination medium of TeSR-E8 Basal Medium, CloneR and laminin LN521 to maintain the cells' High pluripotency and proliferation activity.
It has achieved efficient and stable isolation and amplification of high-active MSCs under animal-free serum conditions, maintained low telomerase activity, and possessed the ability to differentiate across the germ layer, which is suitable for clinical applications.
Smart Images

Figure CN118685353B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of human umbilical cord stem cells, and in particular to a human umbilical cord highly active mesenchymal stem cell and a preparation method and application thereof. Background Art
[0002] Mesenchymal stem cells (MSC) are a group of adult pluripotent stem cells with the ability to self-renew and differentiate. MSC can be obtained from almost all human tissues, such as fat, dental pulp, menstrual blood, placenta, amniotic fluid, umbilical cord and synovial fluid. MSC has immunomodulatory function, secretes cytokines and immune receptors, and regulates the microenvironment in host tissues. It has been proven that it has great therapeutic potential in cardiovascular diseases, autoimmune diseases, vascular ischemia, tissue damage and various degenerative diseases. Therefore, MSC cells themselves and their secretions have broad application prospects in disease prevention and treatment. In view of the functions of the various bioactive substances secreted by them in cell / column repair, inflammation control, etc., MSC and its secretions are also used to prepare cosmetics and health products.
[0003] Since the heterogeneity of MSC morphology and function weakens its therapeutic effect, it introduces differences in clinical evaluation of effectiveness and mechanism research, which may partly explain why the data of MSC-based clinical trials are largely inconsistent. To address the differences in efficacy caused by heterogeneity, it has been reported that more potent and primitive MSC subpopulations have been isolated from MSCs from different tissues. Although these subpopulations have high proliferation and differentiation potential, whether they can maintain multi-lineage differentiation ability, similar to the plasticity of embryonic stem cells, remains to be determined.
[0004] The reported methods for isolating high-potential MSC subpopulations include physical separation, which separates trypsin-resistant, multidirectionally differentiated, and pressure-resistant cells based on their response to trypsin; and separation based on immune phenotype, which separates cell subtypes with pluripotency surface marker molecules by flow cytometry, or introduces exogenous genes for cell re-editing. These separation methods are relatively cumbersome, with low cell activity and low yield, making it difficult to obtain cell therapy quantities for subsequent efficacy studies, and safety is difficult to guarantee. In addition, most culture systems contain animal serum, which is not suitable for clinical translation. Summary of the invention
[0005] The purpose of the present invention is to provide a human umbilical cord high-activity MSC and a preparation method and application thereof, using a simple separation method and a culture condition suitable for clinical transformation application, without the introduction of exogenous genes, to selectively separate a cell population from umbilical cord tissue in a simplified culture system without animal serum, the cell population can be stably and massively expanded, while maintaining low telomerase activity, exhibiting high proliferation activity and pluripotency, and can cross-germ layer differentiation into cells of the ectoderm and mesoderm lineages.
[0006] The above technical objectives of the present invention are achieved through the following technical solutions:
[0007] A method for preparing human umbilical cord highly active MSCs comprises the following steps:
[0008] S1. Reagent preparation;
[0009] S2, primary culture;
[0010] S3. Subculture.
[0011] Preferably, it also includes S4, high-activity MSC cryopreservation.
[0012] Further preferably, S1 includes:
[0013] S11. Preparation of high-activity MSC complete medium: Add TeSR-E8Supplement to TeSR-E8 Basal Medium, mix thoroughly by inversion, then add CloneR, adjust pH to 7.2-7.4 with 6.6% NaHCO3, and store at 4°C for later use;
[0014] S12. Preparation of high-activity MSC culture flask: Slowly thaw the laminin LN521 stock solution at 2-8°C and add 1× DPBS (Ca 2+ / Mg 2+ ) Dilute the laminin LN521 stock solution to make the coating solution, add the coating solution to the culture bottle to evenly cover the entire bottom of the bottle, and incubate at 2-8℃ for later use;
[0015] Further preferably, S2 includes:
[0016] S21, washing the collected human umbilical cord to remove residual blood;
[0017] S22, breaking down the umbilical cord into small tissue pieces and transferring them into a high-activity MSC culture bottle;
[0018] S23, add high-activity MSC complete medium to the high-activity MSC culture bottle, shake the bottle slowly, and place it in an incubator at 37°C and 5% CO2 for primary culture;
[0019] S24, on the 3rd day, add high-activity MSC complete medium, and then change the medium every 3-4 days
[0020] S25. During subculturing, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method;
[0021] Further preferably, S3 includes:
[0022] S31. Take out the cells from the incubator, discard the old culture medium, and gently rinse once with saline;
[0023] S32, primary high-activity MSCs were added with Recombinant Trypsin-EDTA Solution and placed in an incubator at 37°C and 5% CO2 for 3-5 minutes;
[0024] S33, after the cells were completely detached, an equal amount of highly active MSC complete medium was added to terminate the digestion, the cells were collected and added with normal saline, and centrifuged at 1500 rpm for 4 mins;
[0025] S34, discard the supernatant after centrifugation, add high-activity MSC complete medium, gently pipette to mix the cells, and count the number of live cells with trypan blue staining;
[0026] S35, according to 5000 cells / cm 2 The cells were seeded into new high-activity MSC culture flasks at a seeding density of
[0027] S36, placed in an incubator at 37°C and 5% CO2 for expansion culture;
[0028] Further preferably, S4 includes:
[0029] Select highly active MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add highly active MSC complete culture medium to terminate the process. Centrifuge at 1500rpm for 4 minutes, discard the supernatant, gently blow to make the cells uniform, and then divide them into sterile cryopreservation tubes. Put the cryopreservation tubes containing cells into a programmed cooling box in a -80℃ refrigerator. After 4 hours, store them in a -196℃ liquid nitrogen tank for later use.
[0030] Further preferably, in step S11, the ratio of TeSR-E8 Basal Medium, TeSR-E8 Supplement and CloneR is 24:1:1.
[0031] More preferably, in step S12, the laminin LN521 stock solution is diluted to 5 μg / ml.
[0032] Further preferably, in step S21, the human umbilical cord is repeatedly rinsed with physiological saline containing 100u / ml dual antibody.
[0033] A method for preparing human umbilical cord highly active MSCs is provided.
[0034] More preferably, the human umbilical cord highly active MSCs have the functions of wound repair, cell repair, promotion of tissue / cell regeneration and differentiation, immune regulation, anti-aging, and the like.
[0035] A use of the human umbilical cord highly active MSCs in the preparation of cosmetics, health products and medicines.
[0036] More preferably, the human umbilical cord highly active MSCs are in the form of cell culture or lyophilized powder.
[0037] More preferably, the dosage form of the above-mentioned health products and medicines is selected from injections, oral preparations, tablets, capsules or patches.
[0038] More preferably, the above cosmetics also include common auxiliary agents such as antioxidants, stabilizers, emulsifiers, solubilizers, pigments and fragrances.
[0039] A use of the human umbilical cord highly active MSCs in preparing a preparation for preventing, improving or treating aging.
[0040] Further preferably, the human umbilical cord highly active MSCs are used to prepare medicaments for preventing, improving or treating physiological and / or pathological aging / functional impairment of skin, liver, heart, ovary, uterus, testis, muscle, nerve, kidney, immunity, metabolism, or systemic aging / functional impairment.
[0041] Compared with the prior art, the present invention has the following beneficial effects:
[0042] First, improve the culture medium and supporting culture conditions, including TeSR-E8 culture medium, ClonR, cell density and recombinant laminin coating, aiming to create an overall in vivo ecological microenvironment suitable for primitive cells. In this culture condition, TeSR-E8 culture medium does not contain animal origin and has a low protein content. Only one growth factor, ClonR, is added to the entire culture condition, and the use of recombinant laminin coating maintains the high pluripotency of the cells. Under this condition, the primary culture is carried out by whole tissue adhesion. Compared with other separation methods, this method is simple and easy, and the time from the tissue being removed from the body to entering the incubator is shorter, which maximizes and maintains very high cell activity.
[0043] Secondly, the primary culture method allows the original cells or highly pluripotent cells in the tissue to be sorted out from the primary generation, and can be stably passaged and preserved, providing a prerequisite for subsequent expansion.
[0044] Third, compared with conventionally cultured MSCs, highly active MSCs have higher proliferation activity, smaller size, higher nuclear-cytoplasmic ratio, and high expression of embryonic stem cell-related marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepatic and intestinal progenitor cells derived from the three germ layers, indicating that this cell is a sub-totipotent stem cell among highly active MSCs. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 The morphology of umbilical cord HA-MSC and MSC under an inverted phase contrast microscope (×50); 1A: On the 8th day, HA-MSC cells can be seen growing scattered around the tissue mass in a short spindle shape (red circle); 1B: On the 12th day, HA-MSC formed large colonies, and the colonies were arranged like a school of fish; 1C: On the 10th day, MSC cells grew scattered around the tissue mass in a long spindle shape, resembling fibroblasts; 1D: On the 15th day, MSC colonies were arranged in a whorl shape.
[0046] Figure 2 The figures are the cell morphology of HA-MSC and MSC at three passages after passage under an inverted phase contrast microscope (×50); 2A, 2B, and 2C are P3, P6, and P9 of HA-MSC after passage, respectively, and each passage maintains a uniform short cell morphology; 2D, 2E, and 2F are P3, P6, and P9 of MSC after passage, respectively. With the increase of passages, the cell body becomes larger, the edges are irregular, some cells are polygonal, and the number of granules in the cytoplasm increases.
[0047] Figure 3 The P3 generation HA-MSC and MSC were dynamically observed under a holographic living cell microscope for 48 hours.
[0048] Figure 4 These are the growth curves of HA-MSC and MSC; 4A: The growth curves of P3 generation HA-MSC and MSC are typical "S" shapes; 4B: The growth curve of P9 generation HA-MSC remains unchanged, while the growth curve of P9 generation MSC tends to be flat, and the cell proliferation ability decreases.
[0049] Figure 5 is the population doubling time of HA-MSCs and MSCs.
[0050] Figure 6 This is the transmission electron microscopy of HA-MSC; 6A: Bar=5um; 6B: Bar=2um.
[0051] Figure 7 It is a MSC transmission electron microscope; 7A: Bar=5μm; 7B: Bar=2μm.
[0052] Figure 8The nuclear-cytoplasmic ratio of HA-MSC and MSC is measured; 8A, 8B, and 8C are HA-MSC; 8D, 8E, and 8F are MSC, and 8G is the statistical result. Bar = 5 μm. n = 3, **P < 0.01.
[0053] Fig. 9 9A and 9B are the cell cycles of HA-MSC and MSC, respectively.
[0054] Fig.10 10A and 10B are the expression flow cytometry graphs of HA-MSC and MSC surface markers (CD73, CD105, CD90, CD34, CD45); 10A and 10B are the results of HA-MSC and MSC, respectively.
[0055] Fig.11 Figure 11 is the flow cytometric graph of the expression of HA-MSC and MSC surface markers (SSEA-3, SSEA-4, TRA-1-60); Figure 11A and Figure 11B are the results of HA-MSC and MSC, respectively.
[0056] Fig.12 Figure 12A and 12B are the WB electrophoresis images and their expression statistics, respectively.
[0057] Fig.13 It is to identify the tri-lineage differentiation ability of HA-MSC and MSC.
[0058] Fig.14 It is the identification of HA-MSC and MSC ectoderm differentiation marker molecule expression; DAPI locates the cell nucleus, and the secondary antibody is labeled with Cy3 to show red fluorescence. Bar=20μm. n=3, ***P<0.001, **P<0.01. 14A and 14B are the fluorescence imaging and the statistical results of differentiation marker molecule expression, respectively.
[0059] Fig.15 This is the expression identification of mesodermal differentiation marker molecules of HA-MSC and MSC; DAPI locates the cell nucleus, and the secondary antibody is labeled with Cy3 to show red fluorescence. Bar=20μm. n=3, ***P<0.001, **P<0.01. 15A and 15B are the fluorescence imaging and statistical results of differentiation marker molecule expression, respectively.
[0060] Fig.16 It is the identification of HA-MSC and MSC endoderm differentiation marker molecule expression; DAPI locates the cell nucleus, and the secondary antibody is labeled with Cy3 to show red fluorescence. Bar=20μm. n=3, ***P<0.001. 16A and 16B are the fluorescence imaging and differentiation marker molecule expression statistical results, respectively. DETAILED DESCRIPTION
[0061] The present invention will be described in detail below in conjunction with examples, but the examples provided herein are only for illustrative purposes and are not intended to limit the present invention.
[0062] The terms "HA-MSC" and "highly active MSC" and "highly active mesenchymal stem cells" are used interchangeably throughout the text.
[0063] The term "treat" refers to slowing, alleviating, ameliorating or alleviating at least one symptom of a disease, or reversing its onset after onset.
[0064] The term "prevention" refers to the process of acting before a disease occurs to prevent the disease from developing or to lessen the severity of the disease or slow its development.
[0065] The term "agent" as used herein refers to a substance that produces or is capable of producing an effect and may include, but is not limited to, chemicals, pharmaceuticals, drugs, biologics, small molecules, antibodies, nucleic acids, peptides, and proteins.
[0066] The various terms and phrases used in the present invention have general meanings known to those skilled in the art. Even so, the present invention still hopes to provide a more detailed description and explanation of these terms and phrases herein. If the mentioned terms and phrases are inconsistent with the known meanings, the meanings expressed in the present invention shall prevail.
[0067] Example 1: Preparation method of human umbilical cord highly active MSC (HA-MSC)
[0068] 1 Materials
[0069] 1.1 Source of human umbilical cord
[0070] The umbilical cords in this experiment were obtained from the Department of Obstetrics and Gynecology of the 920th Hospital of the Joint Logistics Support Force of the People's Liberation Army. The selected pregnant women were required to have no infectious diseases, no tumor diseases, no family history of genetic diseases, and no congenital diseases in the full-term fetus. With the consent of the pregnant women and their families, the "Informed Consent Form for Umbilical Cord Collection" was signed, and the umbilical cord was collected during delivery. The umbilical cord collection was approved by the Ethics Committee of the 920th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, with the approval number: 2019-036 (Section) -01.
[0071] 1.2 Main instruments
[0072] instrument Manufacturer model Class 100 laminar flow clean bench Suzhou Jiabao Purification Engineering Equipment Co., Ltd. SW-CJ-2F Incubator Shanghai Lishen Scientific Instrument Co., Ltd. Heal Force-240 Inverted phase contrast microscope Olymus Corporation CKX41 3D holographic living cell imaging system NANOLIVE, Switzerland 3D Explorer Centrifuge Shanghai Anting Instrument Factory DL-5-B Flow cytometry BD Company of America Canto Ⅱ 4℃ refrigerator Qingdao Aucma Company Aucma SC-1000 -80℃ Ultra Low Temperature Refrigerator Qingdao Haier Company DW-86L386 Liquid nitrogen tank Sichuan West Asia Company BMT / LNA-200
[0073] 1.3 Main Reagents
[0074] name Manufacturer Model / Article No. DMEM / F12 Israel BI 01-172-1ACS FBS Israel BI 04-001-1A 0.25% trypsin-EDTA GIBCO 2102080 TeSR-E8 Medium STEMCELL 05990 CloneR STEMCELL 05888 Laminin LN 521 Biolamina LN521-02 DPBS (Ca2+ / Mg2+) Israel BI 02-020-1A Recombinant Trypsin-EDTA Solution Israel BI 03-079-1A NutriFreez™ D10 Cryopreservation Medium Israel BI 05-714-1A MTS Promega G3580
[0075] 2. Experimental Methods
[0076] The following steps are involved:
[0077] S1. Reagent preparation
[0078] S1-1. Screening and preparation of culture medium:
[0079] S1-1-1. Based on DMEM / F12, gradually enrich the components of the culture medium, such as replacing bovine serum with human platelet lysate, replacing bovine serum albumin with human serum albumin, and gradually replacing components from animal origin with components from human origin, thereby reducing the immune rejection reaction caused by differences in species origin; there is also the practice of completely abandoning ingredients of animal origin based on DMEM / F12, that is, completely free of ingredients of animal origin (including those of human origin), adding trace elements such as selenium, vitamins, transferrin, insulin, basic fibroblast growth factor, as well as buffer pairs to maintain the pH stability of the solution, antioxidants and other substances. We tried to use DMEM / F12 as the basis, adding human platelet lysate to replace FBS, and observed that the cell proliferation ability remained good, but the in vitro osteogenic and adipogenic abilities were reduced. Then we continued to add transferrin, insulin, basic fibroblast growth factor, etc., and observed that the cell morphology was closer to the original stem cells, the cells were small and translucent, with clear outlines, a high nuclear-cytoplasmic ratio, and the in vitro tri-lineage differentiation ability remained good. The above additives played a key role in maintaining the stemness of stem cells; in order to prevent and control the cloning efficiency of single stem cells, we also added CloneR, and observed that the cells still maintained a good proliferation ability at a low density of seeding. Finally, the HA-MSC complete medium described in S1-1-2 was determined.
[0080] S1-1-2. Preparation of HA-MSC complete culture medium: Add 20 ml TeSR-E8 Supplement to 480 ml TeSR-E8 Basal Medium, invert to mix, then add 20 ml CloneR, adjust the pH value to 7.2-7.4 with 6.6% NaHCO3, and store in a refrigerator at 4°C until use.
[0081] S1-2. Optimization of the culture environment
[0082] S1-2-1, Optimization and screening of coating solution: Starting from how to create a primitive microenvironment for stem cell growth, we considered optimizing the 2D space. We changed from using serum and / or mouse embryonic fibroblast trophoblast to using gelatin, Matrigel, and LN521 to pre-treat the culture flask. After repeated experiments, we found that primary cells rarely grew after gelatin coating. We first excluded the gelatin coating treatment and studied Matrigel and LN521 extracellular matrices. We found that both can maintain a relatively primitive cell state for our isolated cells. Finally, we determined the coating solution and culture flask treatment method as in S1-2-2.
[0083] S1-2-2, coating solution for HA-MSC culture flask: slowly thaw the laminin LN 521 stock solution at 2-8℃, dilute the laminin LN521 stock solution to 5μg / ml with 1×DPBS (Ca2+ / Mg2+), which is the STSC coating solution. Add 5ml of coating solution to each T75cm2, so that it evenly covers the entire bottom of the flask, incubate at 2-8℃ overnight for use, and record the flask as LN521-CoatedT75cm2.
[0084] S2. Primary culture of human umbilical cord HA-MSCs
[0085] S2-1. In a clean bench, repeatedly rinse the collected human umbilical cord with physiological saline containing 100u / ml of dual antibody, remove the residual blood and place it in a 10cm culture dish.
[0086] S2-2, first use tissue scissors to cut the umbilical cord into 1mm pieces 3 Each small tissue block was transferred to a 1.5 ml EP tube. The tissue in the EP tube was separated with iris scissors until it became a paste and then transferred to LN521-Coated T75cm 2 In culture flask.
[0087] S2-3. After adding 3 ml of HA-MSC complete culture medium to each bottle, shake the bottle slowly to evenly disperse the microtissue blocks. Mark the culture time, cell name and generation number on the bottle and place it in an incubator at 37°C and 5% CO2 for primary culture.
[0088] S2-4, on the 3rd day, add 3 ml of complete culture medium, and then change the medium every 3-4 days, and observe the cell growth under an inverted phase contrast microscope. When changing the medium, gently suck up the old culture medium with a pipette and discard it. Move gently and try not to move the tissue blocks attached to the wall.
[0089] S2-5. During subculturing, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method.
[0090] S3. Subculture of HA-MSCs
[0091] When the primary cells grow to about 80% fusion, they need to be subcultured. The specific steps are as follows:
[0092] S3-1. Take out the cells from the incubator, discard the old culture medium in the clean bench, and gently rinse once with saline.
[0093] S3-2. Add 4 ml of Recombinant Trypsin-EDTA Solution to each bottle of primary HA-MSCs and place in an incubator at 37°C and 5% CO2 for 3-5 minutes.
[0094] S3-3. After the cells are completely detached under a microscope, add an equal amount of HA-MSC complete medium to terminate digestion. Collect the cells into a 50 ml centrifuge tube, add physiological saline, and centrifuge at 1500 rpm for 4 minutes.
[0095] S3-4. After centrifugation, discard the supernatant, add 2 ml of complete culture medium, gently pipette to mix the cells, and count the number of living cells by trypan blue staining.
[0096] S3-5, according to 5000 cells / cm 2 The cells were seeded into new LN521-Coated T75 culture flasks at a seeding density of
[0097] S3-6. Mark the culture time, cell name and generation number on the bottle and place it in a 37°C, 5% CO2 incubator for expansion culture. Take photos of each generation of cells.
[0098] S4. Highly active MSC cryopreservation
[0099] Select HA-MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add the corresponding complete medium to terminate the process. Centrifuge at 1500rpm for 4mins and discard the supernatant. Add NutriFreez™D10 Cryopreservation Medium to HA-MSCs, gently blow with a pipette to make the cells uniform, and then divide them into sterile cryopreservation tubes, adding 1.8ml of liquid to each cryopreservation tube. Write the cell name, batch number and cryopreservation time on the cryopreservation tube and keep a record. Place the cryopreservation tube containing cells in a programmed cooling box in a -80℃ refrigerator, and place it in a -196℃ liquid nitrogen tank for 4h for storage.
[0100] Example 2: Preparation method of conventional MSCs
[0101] The preparation method comprises the following steps:
[0102] S1. Reagent preparation
[0103] S1-1. Preparation of MSC complete culture medium: Add 55 ml of fetal bovine serum to 500 ml of DMEM / F12 culture medium, adjust the pH value to 7.2-7.4 with 6.6% NaHCO3, and store in a refrigerator at 4°C for later use.
[0104] S1-2, MSC uses ordinary T75cm 2 Culture flask.
[0105] S2. Primary culture of human umbilical cord MSCs
[0106] S2-1. In a clean bench, repeatedly rinse the collected human umbilical cord with physiological saline containing 100u / ml of dual antibody, remove the residual blood and place it in a 10cm culture dish.
[0107] S2-2, first use tissue scissors to cut the umbilical cord into 1mm pieces 3 Each small tissue block was transferred to a 1.5ml EP tube. The tissue in the EP tube was separated with iris scissors until it became a paste and then transferred to a regular T75cm 2 In culture flask.
[0108] S2-3. After adding 3 ml of MSC complete culture medium to each bottle, shake the bottle slowly to evenly disperse the microtissue blocks. Mark the culture time, cell name and generation number on the bottle and place it in an incubator at 37°C and 5% CO2 for primary culture.
[0109] S2-4, on the 3rd day, add 3 ml of complete culture medium, and then change the medium every 3-4 days, and observe the cell growth under an inverted phase contrast microscope. When changing the medium, gently suck up the old culture medium with a pipette and discard it. Move gently and try not to move the tissue blocks attached to the wall.
[0110] S2-5. During subculturing, the detached tissue pieces are collected and secondary adherent culture can be performed according to the above method.
[0111] S3. Conventional MSC subculture
[0112] When the primary cells grow to about 80% fusion, they need to be subcultured. The specific steps are as follows:
[0113] S3-1. Take out the cells from the incubator, discard the old culture medium in the clean bench, and gently rinse once with saline.
[0114] S3-2. Add 4 ml of 0.25% trypsin-EDTA solution to each bottle of primary MSCs and place them in an incubator at 37°C and 5% CO2 for 3-5 minutes.
[0115] S3-3. After the cells are completely detached under a microscope, add an equal amount of MSC complete medium to terminate digestion. Collect the cells into a 50 ml centrifuge tube, add physiological saline, and centrifuge at 1500 rpm for 4 minutes.
[0116] S3-4. After centrifugation, discard the supernatant, add 2 ml of complete culture medium, gently pipette to mix the cells, and count the number of living cells by trypan blue staining.
[0117] S3-5, according to 5000 cells / cm 2 The cells were seeded into new T75 culture flasks at a seeding density of
[0118] S3-6. Mark the culture time, cell name and generation number on the bottle and place it in a 37°C, 5% CO2 incubator for expansion culture. Take photos of each generation of cells.
[0119] S4. Conventional MSC cryopreservation [SL1]
[0120] Select MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add the corresponding complete medium to terminate the process. Centrifuge at 1500 rpm for 4 minutes and discard the supernatant. Add the prepared freezing solution (containing 10% DMSO and 5% glycerol) to MSCs and adjust the cell density to 4×10 6 / ml, use a pipette to gently blow to make the cells uniform, then divide them into sterile cryopreservation tubes, and add 1.8ml of liquid to each cryopreservation tube. Write the cell name, batch number and cryopreservation time on the cryopreservation tube, and keep a record. Put the cryopreservation tube containing cells into a programmed cooling box and place it in a -80℃ refrigerator. After 4 hours, place it in a -196℃ liquid nitrogen tank for storage.
[0121] Example 3: Comparison of HA-MSCs and conventionally cultured MSCs
[0122] In the following text and in the drawings of the specification, HA-MSC refers to highly active MSC, and MSC refers to conventionally cultured MSC.
[0123] 1. Growth morphology of primary culture of human umbilical cord HA-MSC and MSC
[0124] The two types of stem cells were cultured using the whole tissue adherence method without stripping off the blood vessels and capsule. In the culture system of TeSR-E8 Medium containing 5% ClonR, umbilical cord HA-MSCs were observed to grow scattered around the tissue blocks on the 8th day in a culture bottle coated with laminin LN 521. The umbilical cord HA-MSCs were small in shape, short and spindle-shaped, with a high nuclear-cytoplasmic ratio. A large number of cells were observed to swim out from the periphery of the tissue blocks on the 12th day after the medium was changed ( Figure 1A, 1B). On the 10th day, umbilical cord MSC cells were observed to grow sporadically around the tissue mass in an elongated spindle shape, and on the 15th day, they grew in a spiral-like fusion ( Figure 1 C, 1D). Compared with MSC, HA-MSC is smaller in size, has a higher nuclear-cytoplasmic ratio, and has fewer foreign cells in primary cells.
[0125] 2. Subculture of human umbilical cord HA-MSC and MSC and dynamic observation of 3D holographic living cells
[0126] 2.1 Subculture
[0127] When the primary cells grow to about 80% confluence, they are subcultured. The two stem cells subcultured to P3 maintain their morphology and grow well ( Figure 2 A, 2D). Compared with cells from the same umbilical cord, HA-MSCs maintained a short rod-shaped morphology and good activity until P9. Figure 2 B, 2C); The P9 cells of MSC increased in size, gradually became wider and flatter in shape, some cells were polygonal, and the number of granules in the cytoplasm increased, indicating an aging state ( Figure 2 E, 2F).
[0128] 2.2 3D holographic dynamic observation of living cells
[0129] Under a 3D holographic live cell microscope, HA-MSC and MSC of the P3 generation were dynamically observed for 48 hours, and one cell field of view was selected for dynamic observation. HA-MSC is small in size, with regular cell body edges, little cytoplasm, obvious nucleus and obvious nucleolus, and the genetic material with strong refractive index in the nucleus is dense, indicating that it is in the early stage of division. Before the end of the 48-hour observation, HA-MSC is preparing to enter the division stage, and MSC is larger in size, with irregular cell bodies and a small number of particles visible in the cytoplasm. The cell nucleus is small and the nucleolus is obvious. Before the end of the 48-hour observation, the MSC has not divided ( Figure 3 ). Figure 3 The HA-MSC cell nucleus is large, the cytoplasm is small, and the nuclear staining material gradually increases, indicating that it is about to enter the division stage. The MSC cell volume is irregular, with more cytoplasm, a large nucleus, a prominent nucleolus, and the cell body is constantly changing and wandering (×400).
[0130] 3. Growth curve and population doubling time of human umbilical cord HA-MSCs and MSCs
[0131] 3.1 Growth curve
[0132] The growth curves of HA-MSC and MSC were measured by MTS method. The two types of cells of P3 were in the retention period 2 days after inoculation, and the proliferation was not obvious; they entered the logarithmic growth period 3-7 days later, and the cells grew vigorously and had good activity ( Figure 4A); entered the plateau phase on the 8th day, and the growth curve showed a typical "S" shape. Compared with the same generation HA-MSC, the logarithmic growth curve of P9 MSC was flat and entered the plateau phase earlier, indicating that the cell proliferation ability was reduced ( Figure 4 B).
[0133] 3.2 Population doubling time
[0134] The population doubling time is the time required for the number of cells to double under culture conditions, reflecting the proliferation ability of cells. The population doubling time (PDT) of the two cells was calculated by taking the OD value of the logarithmic growth phase on the growth curve. The PDT of P3-HA-MSC was lower than that of P3-MSC (P < 0.01); the PDT of P9-HA-MSC was significantly lower than that of P9-MSC (P < 0.001); this indicates that the proliferation ability of HA-MSC of P3 and P9 is higher than that of MSC ( Figure 5 ).
[0135] 4. Transmission electron microscopy observation and nuclear-cytoplasmic ratio of human umbilical cord HA-MSC and MSC
[0136] 4.1 Transmission electron microscopy observation
[0137] HA-MSC cells under transmission electron microscopy are slightly edematous. The cell membrane is intact, with abundant pseudopodia and protrusions on the surface. The cell is slender in shape, with uniform intracellular matrix, uniformly distributed organelles, and slight swelling. The cell nucleus (N) is irregular in shape, with an intact nuclear membrane and slightly marginal heterochromatin ( Figure 6 A); Mitochondria (M) are abundant, most of them have clear structures, intact membranes, parallel cristae, and the matrix in some membranes becomes lighter and the cristae decrease; the rough endoplasmic reticulum (RER) is obviously expanded, and a large number of floccules can be seen in the endoplasmic reticulum pool, endoplasmic reticulum retention, Golgi apparatus (Go) hypertrophy, and capsule expansion. Autophagolysosomes (ASS) exist in small quantities, and 2 can be seen in this field of view ( Figure 6 B).
[0138] Under the transmission electron microscope, the MSC cells are slightly edematous as a whole, some organelles are slightly swollen, and the cytoplasm is evenly distributed. The cell membrane is intact, and the surrounding pseudopodia (PS) are abundant and slender, and a small number of organelles in the membrane are vacuolated. The cell nucleus (N) is large and irregular in shape, the nuclear membrane is intact, the perinuclear space is normal, the chromatin is uniform, the nucleolus (Nu) is large, and the structure is dense ( Figure 7 A); Mitochondria (M) are abundant, most of them are slightly swollen, the matrix inside the membrane becomes pale, the cristae are broken and reduced, and in some severe cases, the cristae disappear and become vacuolar; the rough endoplasmic reticulum (RER) is partially expanded, and a small amount of floccules can be seen in the endoplasmic reticulum pool. Lysosomes (Ly) exist occasionally. Glycogen granules (GL) are locally aggregated. There are a large number of autophagic lysosomes (ASS), and 5 can be seen in this field of view ( Figure 7 B).
[0139] 4.2 Nuclear-cytoplasmic ratio
[0140] The nuclear-cytoplasmic ratio was calculated by measuring 3 cells in each group. The nuclear-cytoplasmic ratio of HA-MSC was significantly higher than that of MSC (P < 0.01). Figure 8 .
[0141] 5. Cell Cycle
[0142] By detecting the cell cycle by flow cytometry, 79.48% of HA-MSCs and 63% of MSCs in the P3 generation were in the G0 / G1 phase, which is consistent with the characteristics of MSCs cultured in vitro. HA-MSCs have a high proportion of G0 / G1 phases, proving that they have a high differentiation potential ( Fig. 9 ).
[0143] 6. Expression of surface markers
[0144] Both HA-MSC and MSC highly expressed MSC-related surface markers CD73, CD105, and CD90, and low or no expression of CD34 and CD45 (Table 1, Fig.10 ), which is consistent with the phenotypic characteristics of MSC; HA-MSC partially expressed ESC-related surface markers SSEA-3, SSEA-4 and TRA-1-60, and MSC was affected by the serum in the culture environment, with SSEA-4 expression of 25.8%, and no expression of SSEA-3 and TRA-1-60 (Table 1, Fig.11 ).
[0145] Table 1 Expression percentage of surface markers of HA-MSC and MSC
[0146] CD73 CD105 CD90 CD34 CD45 SSEA-3 SSEA-4 TRA-1-60 HA-MSC 100% 99.8% 95.0% 0.84% 0.23% 26.9% 19.6% 15.7% MSC 99% 99.6% 95.3% 2.26% 0.66% 0 25.8% 0
[0147] 7. Western blot (WB) to detect the expression of pluripotency transcription factors
[0148] WB was used to detect the expression of two stem cell pluripotency transcription factors, and it was found that HA-MSC expressed pluripotency transcription factors SOX2, OCT4, and Nanog. Analysis of the gray value of the target band showed that the expression levels of SOX2 and Nanog were significantly higher than those of MSC (P < 0.001); while MSC only expressed OCT4, and the expression level was no different from that of HA-MSC (P > 0.05) ( Fig.12 ), indicating that HA-MSCs are in an earlier stage of development than MSCs.
[0149] 8. Identification of trilineage differentiation ability
[0150] Adipogenic differentiation: After 14 days of adipogenic differentiation, red lipid droplets can be seen in the cytoplasm after Oil Red O staining; osteogenic differentiation: After 21 days of induction, calcium nodules can be stained red by Alizarin Red; chondrogenic differentiation: After 14 days of induction, cartilage collagen matrix can be seen stained blue by Argine Blue. From the staining degree analysis, the ability of HA-MSC to differentiate into three lines is stronger than that of MSC ( Fig.13 ).
[0151] 9. Expression levels of marker molecules after differentiation of the three germ layers
[0152] After the two types of stem cells were induced to differentiate into three germ layers, two specific markers were selected for each germ layer (ectoderm markers: Nestin, PAX6; mesoderm markers: Meso-CXCR4, Brachyury (T); endoderm markers: Endo-CXCR4, SOX-17) and the expression of markers was detected by immunofluorescence. The results showed that HA-MSC could differentiate into the ectoderm, with the cell morphology showing a neural progenitor cell-like elongated type, and immunofluorescence identification showed the expression of ectoderm-specific markers; at the same time, it could also differentiate into the mesoderm and endoderm and express specific markers of the corresponding germ layers, while MSC could only differentiate into the mesoderm ( Figure 14-16 ).
[0153] In summary, compared with conventionally cultured MSCs, HA-MSCs have higher proliferation activity, smaller size, higher nuclear-cytoplasmic ratio, and highly expressed embryonic stem cell-related marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepatic and intestinal progenitor cells derived from the three germ layers, indicating that this cell is a sub-totipotent stem cell among UC-MSCs.
[0154] This specific embodiment is merely an explanation of the present invention and is not a limitation of the present invention. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed. However, as long as they are within the scope of the claims of the present invention, they are protected by the patent law.
Claims
1. A method for preparing highly active human umbilical cord mesenchymal stem cells (MSCs), It is characterized in that The following steps are involved: S1. Reagent preparation S11. Preparation of high-activity MSC complete medium: Add TeSR-E8 Supplement to TeSR-E8 Basal Medium, invert and mix well, then add CloneR, and use 6.6% NaHCO 3 Adjust the pH value to 7.2-7.4 and store at 4℃ for future use; S12. Preparation of high-activity MSC culture flask: Slowly thaw the laminin LN521 stock solution at 2-8°C and add a solution containing Ca 2+ and Mg 2+ Dilute the laminin LN521 stock solution with 1× DPBS to make the coating solution. Add the coating solution to the culture bottle to evenly cover the entire bottom of the bottle, and incubate at 2-8℃ for later use. S2, primary culture; The stem cells were cultured using the whole tissue adherence method without stripping off the blood vessels and capsule; S21, washing the collected human umbilical cord to remove residual blood; S22, breaking down the umbilical cord into small tissue pieces and transferring them into a high-activity MSC culture bottle; S23, add high-activity MSC complete medium to the high-activity MSC culture bottle, shake the bottle slowly, and place it at 37°C and 5% CO 2 Primary culture was carried out in an incubator; S24, on day 3, add high-activity MSC complete medium, and then change the medium every 3-4 days; S25. During the passage, the detached tissue pieces were collected and cultured for the second time according to the above method; S3, subculture; When the primary cells grow to about 80% confluence, subculture is performed; S31. Take out the cells from the incubator, discard the old culture medium, and gently rinse once with saline; S32, primary high-activity MSCs were added with Recombinant Trypsin-EDTA Solution and placed at 37°C and 5% CO 2 Incubator for 3-5mins; S33, after the cells were completely detached, an equal amount of highly active MSC complete medium was added to terminate the digestion, the cells were collected and added with normal saline, and centrifuged at 1500 rpm for 4 mins; S34, discard the supernatant after centrifugation, add high-activity MSC complete medium, gently pipette to mix the cells, and count the number of live cells with trypan blue staining; S35, according to 5000 cells / cm 2 The cells were seeded into new high-activity MSC culture flasks at a seeding density of S36, placed at 37°C, 5% CO 2 The cells were cultured in an incubator for expansion; S4. Cryopreservation of highly active MSCs. The specific steps are as follows: Select highly active MSCs in the logarithmic growth phase and digest them with Recombinant Trypsin-EDTA Solution. After the cells shrink and become round, add highly active MSC complete medium to terminate the digestion. Centrifuge at 1500rpm for 4mins, discard the supernatant, gently blow to make the cells uniform, and then divide them into sterile cryopreservation tubes. Put the cryopreservation tubes containing cells into a programmed cooling box in a -80℃ refrigerator. After 4h, store them in a -196℃ liquid nitrogen tank for later use; In step S11, the ratio of TeSR-E8 Basal Medium, TeSR-E8 Supplement, and CloneR is 24:1:1; In step S12, the laminin LN521 stock solution is diluted to 5 μg / ml; In step S21, the human umbilical cord is repeatedly rinsed with physiological saline containing 100u / ml dual antibody.
2. Human umbilical cord highly active MSCs prepared by the method for preparing human umbilical cord highly active MSCs according to claim 1.
